Review Process Reform
AstraZeneca and Daiichi Sankyo’s Enhertu Denied NICE Recommendation for NHS Use, Prompting Calls for Review Process Reform
Enhertu, NICE, AstraZeneca, Daiichi Sankyo, NHS, breast cancer treatment, cost-effectiveness, pricing dispute, review process reform